Literature DB >> 26009247

A novel immunoassay to measure total serum lymphotoxin-α levels in the presence of an anti-LTα therapeutic antibody.

Judy Young1, Allen Nguyen2, Zhihua Julia Qiu3, Yong Ying3, Xiaoying Gao3, Chae Reed4, Anan Chuntharapai4, Rong Deng5, Jeff Lutman5, Jane Grogan6, Wai Lee Wong2, Laura DeForge2.   

Abstract

During drug development, measurement of suitable pharmacodynamic biomarkers is key to establishing in vivo drug activity. Binding of monoclonal antibody (mAb) therapeutics to soluble target proteins often results in elevated serum levels of their target antigen, and measuring total (free and bound) concentration of the target antigen can be an important means of demonstrating that the mAb has reached its specific target. However, accurately measuring soluble circulating antigen in preclinical or clinical samples in the presence of a therapeutic mAb presents a bioanalytical challenge. Particularly in the case of low molecular weight and/or multimeric targets, epitopes for capture and detection of the target by reagent antibodies can be obscured by bound therapeutic mAb. Lymphotoxin-alpha (LTα) is a cytokine in the TNF superfamily that has been implicated in the pathophysiology of autoimmune disease, and is a therapeutic target for neutralizing mAb. During preclinical safety studies in cynomolgus macaques, we encountered difficulties in measuring total LTα in serum of dosed animals. When serum LTα trimer was saturated with the anti-LTα mAb, binding of two reagent antibodies, as required for a classic sandwich ELISA, was not feasible, and dissociation methods were also found to be unsuitable. We therefore developed an approach in which excess anti-LTα mAb was added to the in vitro assay system to fully saturate all binding sites, and an anti-idiotypic antibody was used to detect bound therapeutic antibody. Using this method, total LTα could be accurately measured in cynomolgus macaque serum, and was observed to increase with increasing anti-LTα therapeutic mAb dose. Additional in vitro studies demonstrated that the method worked equally well in human serum. This assay strategy will be useful for quantifying total concentrations of other small and/or multimeric target proteins in the presence of a therapeutic antibody.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarker; Lymphotoxin-alpha; Monoclonal antibody; Pharmacodynamics; Pharmacokinetics

Mesh:

Substances:

Year:  2015        PMID: 26009247     DOI: 10.1016/j.jim.2015.05.006

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  1 in total

Review 1.  The role of lymphotoxin-α in rheumatoid arthritis.

Authors:  Tomohiro Hirose; Yuri Fukuma; Ayumu Takeshita; Keiichiro Nishida
Journal:  Inflamm Res       Date:  2018-03-14       Impact factor: 4.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.